Purpose: We aimed to investigate basic information, clinical findings, treatments for tumor, pathology and outcomes of HIV-positive patients diagnosed renal cell carcinoma(RCC). Patients and Methods: We collected 19 patients from 2012 to 2020 who diagnosed RCC with HIV- positive. A retrospective analyze was performed on their hospitalization course and tumor related parameters, including basic information, clinical findings, HIV associated datas, pathology, treatments for tumor and outcomes.Results: In our study, patients were diagnosed RCC at the median age 51. Males took a great part(17 males,89%) in all patients, while only 2 females were diagnosed. The median CD4+ T-lymphocyte cell count was 462 cells/ul when diagnosed RCC(range from 111 cells/ul to 1536 cells/ul). 11 patients diagnosed RCC and HIV infection at the same time, who may have high viral load and low CD4+ T-lymphocyte cell count. 8 patients accepted a median HAART for 30 months(range from 11 months to 108months) prior to diagnosis of RCC. All the patients performed operations successfully, and 4 of them performed partial nephrecotomy. Only 1 patient was identified with chromophobe cell carcinoma, 1 with partially clear cell and partialy papillary carcinoma, and 17 with clear cell carcinoma. 2 of the patients with Fuhrman grade2-3 accepted cytokine therapy with IL-2 and IFN-α. 2 patients died of lung metastasis one year and six months after surgery respectively, even though 1 patient accepted full dose targeted therapy (Sorafenib) for 3 months, and one refused adjuvant therapy. The remaining 17 patients are still alive at a median follow-up of 34 months, however 1 patient live with lung and brain metastases at last follow-up of 3 years after surgery.Conclusions: RCC Patients with HIV-positive were similar to general population in terms of clinical characters, treatment measures, and pathology. RCC patients with HIV- positive seemed like to obey the same clinical practice guideline as in general population. The outcomes of HIV-positive patients with partial nephrectomy are not inferior to patients with radical nephrectomy. Further more experience in targeted therapy and immunal therapy( PD-1/ PD-L1 inhibitors) needs to be learned.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.